ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer Post author:admERY Post published:May 6, 2014 Post category:Newsroom ERYTECH announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer. You Might Also Like ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies February 15, 2023 ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015 February 23, 2016 ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 November 5, 2020
ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies February 15, 2023
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 November 5, 2020